189 0 Kommentare New Real-World Data Further Support the Use of Veklury (Remdesivir) for People Hospitalized With COVID-19

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from three real-world retrospective studies being presented at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).

One study showed Veklury (remdesivir) was associated with a reduced risk of certain long-COVID symptoms in people who were hospitalized for COVID-19.
In a separate study, Veklury use was associated with significantly reduced mortality among people who were immunocompromised and were hospitalized for COVID-19 during the Omicron period (Dec’21 – April’23), irrespective of oxygen requirements.
A third analysis revealed that treatment with Veklury and dexamethasone among patients hospitalized for COVID-19 was associated with reduced mortality as compared to treatment with only dexamethasone, irrespective of oxygen requirements.

“The real-world data presented at CROI continue to reinforce the strong efficacy and safety profile of Veklury, as well as the potential benefit of Veklury for people affected by COVID-19,” said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. “As we enter the fourth year of COVID-19, Veklury remains the antiviral standard of care for people hospitalized for COVID-19. These latest data add to our scientific understanding about Veklury’s potential role in reducing mortality, including in immunocompromised people, and helping to reduce the risk of getting long-COVID symptoms.”

Lesen Sie auch

Kurs bricht ein

Schott Pharma: Trübe Aussichten führen zu drastischem Kurseinbruch

15.05.24, 17:33

Technische Analyse

Gewinne abgegeben! Wird die Aktie von Bayer jetzt verkauft?

15.05.24, 06:27

Ihre wichtigsten Termine

Zahlen-Update von: Burberry, Allianz, Eon, Tui, Dermapharm, Freenet und Fraport

15.05.24, 04:30

Shortseller bluten

Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein!

14.05.24, 12:52

To understand Veklury’s potential impact on the risk of long-COVID, also known as post-COVID conditions (PCC), Gilead analyzed HealthVerity data from 52,006 patients. Results from the study demonstrate that Veklury use was associated with a 10% lower risk of any PCC in both age groups analyzed: HR 0.90 (95% confidence interval [CI]: 0.86–0.93) in those <65 years old and HR 0.90 (95% CI: 0.86–0.95) in those ≥65 years old. Veklury use was associated with lower risk for 6 of 16 individual symptoms/diagnoses in the ≥65 age group (including cognitive dysfunction, cerebrovascular disease, neuropsychiatric features, diarrhea, chest pain, and dysautonomia) and for 8 of 16 individual symptoms/diagnoses in the <65 age group (including the 6 symptoms in the ≥65 age group, as well as thromboembolic disease and headache). Results from this analysis build on existing evidence that support the importance of treating COVID-19 early in the disease course with an antiviral.

Seite 1 von 5

Seite 2 ►